The study evaluates whether HIP-engineered insulin-producing pancreatic cells can be transplanted safely and help to regain insulin production in individuals with type 1 diabetes without need of ...

Sana's first-in-human study shows HIP technology allows islet cells to avoid immune rejection and produce insulin without immunosuppression. Reliance on initial results: The press release heavily ...

Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...

Patented Green Extraction Technology Transforms Black Soldier Fly Waste Into Pure Insulin at 50% of Synthetic Insulin Cost Half-price natural Insulin is finally within reach, thanks to generational ...

Madison, Wisconsin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Regenerative Medical Solutions (RMS), a Wisconsin-based biotech company, has been awarded a peer-reviewed National Institutes of Health (NIH) ...

On Tuesday, Sana Biotechnology Inc (NASDAQ:SANA) released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s ...

The beta cells of the pancreas don’t need the assistance of other pancreatic cells to produce insulin, according to new research. The findings are not only a potential game-changer for diabetics, but ...

Data Demonstrate that Sana’s Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...